Skip to content

OOSTVELD - PHARMA

Active Private limited companyfounded 2001active for 25 yearsOostveld Kouter 171, 9920 LievegemKBO/BCE: BE 0476.087.480 subsidiary of

Lifetime

20 annual accounts with figures on one time axis, 24 filings since 2002
peak of €393,510 in 2025
€393,510▲ 3.3%
peak of €218,510 in 2021
€135,281▼ 3.6%
peak of €615,002 in 2010
€555,023unchanged
€702,932▼ 5.5%
peak of 2.4 FTE in 2019
1.9 FTEunchanged
Board2 names since 2010
2 directors and 1 other
Owners
100%
Documentsfilings and deeds
24-06-202637 days before the deadline
2025abbreviated format
Dividend €105,281

Key points

from the 2025 annual accounts

Equity

€555,023 =
555,0232024+135,281Profit-105,281Dividend-30,000Other555,0232025

OOSTVELD - PHARMA paid out €105,281 in dividends. That is 78% of the 2025 profit.

Staff

2 employees on 31-12-2025
102021212022012023112024112025

In 2025, 1 employee joined and 1 left.

Filings

24 annual accounts since 2002
AprilJune31 JulyOctober20102020

The last five annual accounts were filed 26 to 58 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,389 companies had the same profile as OOSTVELD - PHARMA has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,389 companies, not a prediction for OOSTVELD - PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 01-01-2010
Director, , since 01-07-2018
  • 100%score equity €991,367 (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0476087480
(director) and (director) change roles acts as permanent representative · Director discharge: · Director discharge: · General meeting of 28-07-2023 · Gazette deed
acts as permanent representative General meeting of 01-07-2018 · Gazette deed
Environmental permit granted Bouwen of herbouwen, Slopen van niet vrijstaande gebouwen of constructies, Verbouwen en/of uitbreiden zonder functiewijziging en zonder wijziging van aantal woongelegenheden · Lievegem
All 33 events

Comparable companies

same main activity, similar in size and age
Company
OOSTVELD - PHARMA Lievegem €1.3m €393,510 44.1% 1.9
APOTHEEK PLATTEEUW B Ronse €1.3m €347,519 46.3% 2
APOTHEEK MAERTENS Wevelgem €1.3m €382,222 26.3% 1.8
PHARMACIE CARRA Seraing €1.4m €395,231 51.5% 2
PHARMACIE DEBOR-MORDANT Marche-en-Famenne €1.2m €390,948 41.7% 2
APOTHEEK WELLE Denderleeuw €1.2m €415,863 55.6% 1.8
APOTHEEK BAUWENS DONALD Sint-Niklaas €1.7m €372,353 24.0% 1.9

These companies have the same main activity as OOSTVELD - PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.2m and €1.7m, founded between 2001 and 2007.

Official details

Source: KBO
Status
Active since 15-11-2001Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2024
Establishment unit
2.095.497.8299920 Lievegem, since 07-01-2002
Financial year end
31 December
Peppol
Reachable since 25-09-2025
Company details

Annual accounts 2025

≈ €1.4mestimated
€1.3m▼ 3.1%
Employeeson 31-12-2025
2=
Filing
Filed on 24-06-2026, 37 days before the end of the filing period
Financials

Insights on OOSTVELD - PHARMA

OOSTVELD - PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €204,900 in 2006 to €393,510 in 2025.

The balance sheet grew most in 2019 through fixed assets, financed with long-term debt.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about OOSTVELD - PHARMA

What is the company number of OOSTVELD - PHARMA?
The company number of OOSTVELD - PHARMA is 0476.087.480. The VAT number is the same number with BE in front: BE 0476.087.480.
Where is OOSTVELD - PHARMA based?
The registered office is at Oostveld Kouter 171, 9920 Lievegem.Company details
What does OOSTVELD - PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of OOSTVELD - PHARMA?
OOSTVELD - PHARMA is a private limited company (BV).
When was OOSTVELD - PHARMA founded?
OOSTVELD - PHARMA was founded on 15-11-2001.
Is OOSTVELD - PHARMA still active?
Yes, OOSTVELD - PHARMA is an active enterprise in the KBO register.
How many employees does OOSTVELD - PHARMA have?
OOSTVELD - PHARMA had an average of 1.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does OOSTVELD - PHARMA fall under?
In its 2024 annual accounts, OOSTVELD - PHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of OOSTVELD - PHARMA?
The turnover in financial year 2025 is ≈ €1.4m. This figure is estimated from the gross margin of €393,510 and 42 comparable companies (NACE 477). It probably lies between €1.1m and €1.9m.
Is OOSTVELD - PHARMA profitable?
In financial year 2025, OOSTVELD - PHARMA made a profit of €135,281.
Where can I find the annual accounts of OOSTVELD - PHARMA?
OOSTVELD - PHARMA filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of OOSTVELD - PHARMA due?
OOSTVELD - PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.